Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Carbazoles / therapeutic use*
  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / genetics
  • Female
  • Humans
  • Kidney Neoplasms / diagnosis
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics
  • Male
  • Oncogene Proteins, Fusion / antagonists & inhibitors
  • Oncogene Proteins, Fusion / genetics*
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Carbazoles
  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Piperidines
  • Protein Kinase Inhibitors
  • alectinib